242 related articles for article (PubMed ID: 23235151)
1. Mast cells produce novel shorter forms of perlecan that contain functional endorepellin: a role in angiogenesis and wound healing.
Jung M; Lord MS; Cheng B; Lyons JG; Alkhouri H; Hughes JM; McCarthy SJ; Iozzo RV; Whitelock JM
J Biol Chem; 2013 Feb; 288(5):3289-304. PubMed ID: 23235151
[TBL] [Abstract][Full Text] [Related]
2. Endorepellin, the angiostatic module of perlecan, interacts with both the α2β1 integrin and vascular endothelial growth factor receptor 2 (VEGFR2): a dual receptor antagonism.
Goyal A; Pal N; Concannon M; Paul M; Doran M; Poluzzi C; Sekiguchi K; Whitelock JM; Neill T; Iozzo RV
J Biol Chem; 2011 Jul; 286(29):25947-62. PubMed ID: 21596751
[TBL] [Abstract][Full Text] [Related]
3. Transcriptional complexity of the HSPG2 gene in the human mast cell line, HMC-1.
Lord MS; Jung M; Cheng B; Whitelock JM
Matrix Biol; 2014 Apr; 35():123-31. PubMed ID: 24365408
[TBL] [Abstract][Full Text] [Related]
4. Endorepellin causes endothelial cell disassembly of actin cytoskeleton and focal adhesions through alpha2beta1 integrin.
Bix G; Fu J; Gonzalez EM; Macro L; Barker A; Campbell S; Zutter MM; Santoro SA; Kim JK; Höök M; Reed CC; Iozzo RV
J Cell Biol; 2004 Jul; 166(1):97-109. PubMed ID: 15240572
[TBL] [Abstract][Full Text] [Related]
5. Endorepellin laminin-like globular 1/2 domains bind Ig3-5 of vascular endothelial growth factor (VEGF) receptor 2 and block pro-angiogenic signaling by VEGFA in endothelial cells.
Willis CD; Poluzzi C; Mongiat M; Iozzo RV
FEBS J; 2013 May; 280(10):2271-84. PubMed ID: 23374253
[TBL] [Abstract][Full Text] [Related]
6. Integrin alpha2beta1 is the required receptor for endorepellin angiostatic activity.
Woodall BP; Nyström A; Iozzo RA; Eble JA; Niland S; Krieg T; Eckes B; Pozzi A; Iozzo RV
J Biol Chem; 2008 Jan; 283(4):2335-43. PubMed ID: 18024432
[TBL] [Abstract][Full Text] [Related]
7. Endorepellin, the C-terminal angiostatic module of perlecan, enhances collagen-platelet responses via the alpha2beta1-integrin receptor.
Bix G; Iozzo RA; Woodall B; Burrows M; McQuillan A; Campbell S; Fields GB; Iozzo RV
Blood; 2007 May; 109(9):3745-8. PubMed ID: 17197432
[TBL] [Abstract][Full Text] [Related]
8. The role of perlecan and endorepellin in the control of tumor angiogenesis and endothelial cell autophagy.
Douglass S; Goyal A; Iozzo RV
Connect Tissue Res; 2015; 56(5):381-91. PubMed ID: 26181327
[TBL] [Abstract][Full Text] [Related]
9. Role of tyrosine phosphatase SHP-1 in the mechanism of endorepellin angiostatic activity.
Nyström A; Shaik ZP; Gullberg D; Krieg T; Eckes B; Zent R; Pozzi A; Iozzo RV
Blood; 2009 Nov; 114(23):4897-906. PubMed ID: 19789387
[TBL] [Abstract][Full Text] [Related]
10. Endorepellin in vivo: targeting the tumor vasculature and retarding cancer growth and metabolism.
Bix G; Castello R; Burrows M; Zoeller JJ; Weech M; Iozzo RA; Cardi C; Thakur ML; Barker CA; Camphausen K; Iozzo RV
J Natl Cancer Inst; 2006 Nov; 98(22):1634-46. PubMed ID: 17105986
[TBL] [Abstract][Full Text] [Related]
11. Endorepellin affects angiogenesis by antagonizing diverse vascular endothelial growth factor receptor 2 (VEGFR2)-evoked signaling pathways: transcriptional repression of hypoxia-inducible factor 1α and VEGFA and concurrent inhibition of nuclear factor of activated T cell 1 (NFAT1) activation.
Goyal A; Poluzzi C; Willis CD; Smythies J; Shellard A; Neill T; Iozzo RV
J Biol Chem; 2012 Dec; 287(52):43543-56. PubMed ID: 23060442
[TBL] [Abstract][Full Text] [Related]
12. Endorepellin evokes autophagy in endothelial cells.
Poluzzi C; Casulli J; Goyal A; Mercer TJ; Neill T; Iozzo RV
J Biol Chem; 2014 Jun; 289(23):16114-28. PubMed ID: 24737315
[TBL] [Abstract][Full Text] [Related]
13. Endorepellin, a novel inhibitor of angiogenesis derived from the C terminus of perlecan.
Mongiat M; Sweeney SM; San Antonio JD; Fu J; Iozzo RV
J Biol Chem; 2003 Feb; 278(6):4238-49. PubMed ID: 12435733
[TBL] [Abstract][Full Text] [Related]
14. The role of vascular-derived perlecan in modulating cell adhesion, proliferation and growth factor signaling.
Lord MS; Chuang CY; Melrose J; Davies MJ; Iozzo RV; Whitelock JM
Matrix Biol; 2014 Apr; 35():112-22. PubMed ID: 24509440
[TBL] [Abstract][Full Text] [Related]
15. Perlecan, a modular instructive proteoglycan with diverse functional properties.
Melrose J
Int J Biochem Cell Biol; 2020 Nov; 128():105849. PubMed ID: 32947020
[TBL] [Abstract][Full Text] [Related]
16. Recombinant Domain V of Human Perlecan Is a Bioactive Vascular Proteoglycan.
Rnjak-Kovacina J; Tang F; Lin X; Whitelock JM; Lord MS
Biotechnol J; 2017 Dec; 12(12):. PubMed ID: 28846206
[TBL] [Abstract][Full Text] [Related]
17. A current view of perlecan in physiology and pathology: A mosaic of functions.
Gubbiotti MA; Neill T; Iozzo RV
Matrix Biol; 2017 Jan; 57-58():285-298. PubMed ID: 27613501
[TBL] [Abstract][Full Text] [Related]
18. A novel peptide sequence in perlecan domain IV supports cell adhesion, spreading and FAK activation.
Farach-Carson MC; Brown AJ; Lynam M; Safran JB; Carson DD
Matrix Biol; 2008 Mar; 27(2):150-60. PubMed ID: 17997086
[TBL] [Abstract][Full Text] [Related]
19. Crystal structure of the LG3 domain of endorepellin, an angiogenesis inhibitor.
Le BV; Kim H; Choi J; Kim JH; Hahn MJ; Lee C; Kim KK; Hwang HY
J Mol Biol; 2011 Nov; 414(2):231-42. PubMed ID: 21996443
[TBL] [Abstract][Full Text] [Related]
20. BMP-1/Tolloid-like metalloproteases process endorepellin, the angiostatic C-terminal fragment of perlecan.
Gonzalez EM; Reed CC; Bix G; Fu J; Zhang Y; Gopalakrishnan B; Greenspan DS; Iozzo RV
J Biol Chem; 2005 Feb; 280(8):7080-7. PubMed ID: 15591058
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
